Evidence map›Paper›PMID 29254189›Full record

ArticleOncotarget2017

The component formula of

Lei Bi, Xiaojing Yan, Ye Yang, Lei Qian, Yuan Tian, Jian-Hua Mao, Weiping Chen

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Experimental and therapeutic medicine · 2023
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Activation of ER Stress-Dependent miR-216b Has a Critical Role inInternational journal of molecular sciences · 2018
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Lei Bi *School of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Xiaojing Yan *Changzhou Affiliated Hospital, Nanjing University of Chinese Medicine, Changzhou 213003, China.
Ye YangSchool of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Lei QianSchool of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Yuan TianSchool of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Jian-Hua MaoBiological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
Weiping ChenSchool of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Nanjing University of Chinese Medicine · CNLawrence Berkeley National Laboratory · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer still remains the leading cause of cancer-related death worldwide. It is an urgent need for development of novel therapeutic agents to improve current treatment of this disease. Here we investigate whether the effective component formula of traditional Chinese Medicine could serve as new potential therapeutic drugs to treat lung cancer. We optimize the most effective component formula of

Indexed as

orthogonal array designPI3K/AKT signaling pathwayPTEN phosphorylationthe component formula of Salvia miltiorrhiza and Panax ginseng (FMG)

Identifiers

PMID29254189
PMCPMC5731899
OpenAlexW2758779281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.